Increase Response Rates News Today

Gout is a risk factor for CKD progression, so investigators probed the effect of pegloticase-methotrexate treatment on kidney function.

Gout is a risk factor for CKD progression, so investigators probed the effect of pegloticase-methotrexate treatment on kidney function.

Pegloticase combined with methotrexate leads to a better drug response with less infusion reaction among patients with uncontrolled gout.

At month 12, 60.0% of the MTX group and 30.8% of the placebo group achieved treatment response.

-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 -- -- Imaging

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the... | November 5, 2022

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the treatment

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the treatment period --DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate K...

Meeting plenary session to feature 12-Month data from MIRROR randomized controlled trial of KRYSTEXXA (pegloticase) injection with methotrexate - Horizon Therapeutics plc (Nasdaq: HZNP) today announced

-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to KRYSTEXXA with methotrexate compared to KRYSTEXXA alone -- -- Trial